Logo for Alkermes plc

Alkermes Investor Relations Material

Latest events

Logo for Alkermes plc

Q1 2024

Alkermes
Logo for Alkermes

Q1 2024

1 May, 2024
Logo for Alkermes

Q4 2023

15 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Alkermes plc

Access all reports
Alkermes plc is a biopharmaceutical company. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective disorder; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.